Abstract Number: 0302 • ACR Convergence 2021
Loss of TAM Receptor Mer Contributes to Sjögren’s Syndrome–like Disease in Mice
Background/Purpose: Sjögren’s syndrome (SjS) is a chronic autoimmune disease primarily involving the exocrine glands where the involvement of the innate immune system is largely uncharacterized.…Abstract Number: 0318 • ACR Convergence 2021
Correlation Between Prognostic Nutritional Index and Primary Sjögren’s Syndrome Disease Activity
Background/Purpose: Since primary Sjögren’s Syndrome (pSS) is a very heterogeneous disease with systemic manifestations, factors influencing the outcome of patients with pSS need to be…Abstract Number: 1841 • ACR Convergence 2021
Presence of Autoantibodies to Dense-Fine-Speckled 70 (DFS70) Do Not Necessarily Rule out Connective Tissue Diseases
Background/Purpose: Antinuclear antibodies (ANA) are serological markers for the presence of connective tissue diseases [1]. In some patients, a pattern can be detected in ANA…Abstract Number: 0303 • ACR Convergence 2021
Extraglandular Manifestations as Initial Presentation in a Cohort of Patients with Primary Sjögren’s Syndrome
Background/Purpose: Primary Sjögren's Syndrome (pSS) is a systemic autoimmune disease which is mostly characterized by the presence of xerophthalmia and xerostomia, caused by the lymphoplasmacytic…Abstract Number: 0319 • ACR Convergence 2021
Assessment of EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI) Domains in Routine Clinical Practice in an Integrated Delivery Network in the United States
Background/Purpose: Sjögren's syndrome (SS) is a chronic autoimmune disease associated with diverse phenotypes, which may include systemic disease activity. In real-world practice, the clinical presentation…Abstract Number: 1908 • ACR Convergence 2021
Interferon (IFN)-Stimulated Gene 15: A Novel Biomarker for Lymphoma Development in Sjögren’s Syndrome
Background/Purpose: Primary Sjögren’s syndrome (SS), an autoimmune exocrinopathy, is expressed either as a local disease or as a systemic illness with an enhanced risk for…Abstract Number: 0304 • ACR Convergence 2021
Renal Involvement in Sjőgren’s Syndrome: Predictors and Impact on Patient Outcome
Background/Purpose: Renal disease in primary Sjogren's syndrome (pSS) can occur in form of tubulointerstitial nephritis (TIN) or glomerulonephritis (GN). Data from India on pSS is…Abstract Number: 0320 • ACR Convergence 2021
Performance of the Clinical Trials ESSDAI (ClinTrialsESSDAI), an Adjusted ESSDAI Score, in Two Randomised Clinical Trials in Patients with Primary Sjögren’s Syndrome
Background/Purpose: Recent randomised controlled trials (RCTs) in primary Sjögren’s syndrome (pSS) failed to show clinical efficacy.1-3 Several RCTs used the EULAR Sjögren’s Syndrome Disease Activity…Abstract Number: 1935 • ACR Convergence 2021
Skewed Escape from X-inactivation: Insights into the Female Bias of Sjögren’s Syndrome
Background/Purpose: Many autoimmune diseases feature increased prevalence in females, with primary Sjögren's syndrome (pSS) being the most female-predominant autoimmune disease with a female-to-male ratio of…Abstract Number: 0305 • ACR Convergence 2021
Artificial Neural Networks Approaches to Predict Myocardial Fibrosis in Primary Sjögren Syndrome Patients Without Cardiac Symptoms
Background/Purpose: A recent meta-analysis of cardiovascular diseases demonstrated that the odds of heart failure (HF) was more than 2.54-fold higher in primary Sjögren syndrome (pSS)…Abstract Number: 0321 • ACR Convergence 2021
Sequential Administration of Belimumab and Rituximab in Primary Sjögren’s Syndrome Reduces Minor Salivary Gland–Resident B Cells and Delays B-Cell Repopulation in Circulation
Background/Purpose: Primary Sjögren’s syndrome (pSS) is characterized by B-cell hyperactivity and elevated serum and saliva B-lymphocyte stimulator (BLyS) levels.1 Sequential administration of belimumab (BEL; anti-BLyS)…Abstract Number: 0306 • ACR Convergence 2021
Allergic Disorders in Primary Sjögren’s Syndrome Compared with Rheumatoid Arthritis
Background/Purpose: Allergic disorders are occasionally seen in patients with primary Sjögren's syndrome (pSS) [1]. Risk factors are unclear for allergic disorders.We aimed to compare the…Abstract Number: 0322 • ACR Convergence 2021
Histopathological Changes in Parotid and Labial Salivary Gland Tissue in Primary Sjögren’s Syndrome Patients After Abatacept Treatment
Background/Purpose: In a previous open-label phase II study, we showed that abatacept treatment might inhibit local formation of autoreactive memory B cells in parotid glands…Abstract Number: 0307 • ACR Convergence 2021
Cerebellar Ataxia in Primary Sjogren’s Syndrome, Is Gluten Sensitivity the Answer?
Background/Purpose: Cerebellar ataxia is an uncommon neurological complication of Primary Sjogren’s Syndrome (PSS), with case reports being the highest level of evidence available. The underlying…Abstract Number: 0323 • ACR Convergence 2021
Ro Positivity Is an Under‐Recognised Poor Prognostic Marker in Systemic Lupus Erythematosus Patients
Background/Purpose: Antibodies to Ro60 (SSA) or Ro52 (SSB) have been described as one of the defining autoantibodies in Sjogren syndrome but they are also commonly…
ACR Meeting Abstracts